Dallas, Texas (PRWEB) November 10, 2012
The US seasonal influenza vaccine market is the most attractive of those covered in the report in terms of value. It is forecast to increase from $1.6 billion in 2011 to $2.2 billion in 2018 at a CAGR of 4.8%, due to the growth of the aging population, higher disease awareness and the fact that being vaccinated has become more convenient. The UK on the other hand has the most attractive market in terms of growth rate, forecast to grow at CAGR of 6.3% between 2011 and 2018. Germany’s market is also attractive and is forecast to grow at a CAGR of 2.7% between 2011 and 2018 from $385.5m to $465m. The market in Japan is forecast to grow at CAGR of 1.6% between 2011 and 2018 to reach $621.5m by 2018, driven by the threat of pandemic influenza and higher awareness of influenza vaccination. The government-run influenza immunization program is also helping to increase vaccination coverage.
Analysis shows that the R&D pipeline for seasonal influenza vaccines market comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. The market is currently dominated by trivalent vaccines but will witness the launch of quadrivalent vaccines in the near future.
Buy your copy of this report @ http://www.reportsnreports.com/reports/202051-seasonal-influenza-vaccines-market-in-top-seven-countries-to-2018-next-generation-quadrivalent-vaccines-to-dominate-the-market-by-offering-broader-protection-via-single-dose.html.
The vaccine industry has seen changes in the past year, and these are covered in the report “Vaccines 2012: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry”. This report examines the market for vaccines used in humans to previous various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer’s disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attach, Helicobacter pylori infection, multiple sclerosis, Parkinson’s disease, West Nile virus (WNV) infection, etc. The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth through 2011 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions.
Included in this report are current market size and forecast for the following vaccines:
- Other Pediatric
- Cervical Cancer
- Travel; DT; Misc.
One of the key factors contributing to the growth of global pneumococcal vaccine market is the increase in the aging population. The Global Pneumococcal Vaccine industry has also been witnessing the trend of the increase in market consolidation. However, the emergence of regional players could pose a challenge to the growth of this market.
The research report, the Global Pneumococcal Vaccine Market 2011-2015, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Pneumococcal Polysaccharide Vaccines and Pneumococcal Conjugate Vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include GlaxoSmithKline plc. Merck and Co. Inc. and Pfizer Inc.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.
Buy your copy of this report @ http://www.reportsnreports.com/reports/195950-global-pneumococcal-vaccine-market-2011-2015.html.
Browse all reports on Vaccine market @ http://www.reportsnreports.com/tags/vaccine-market-research.html.
Contact sales (at) reportsandreports (dot) com for further information.
ReportsnReports.com is an online market research reports (http://www.reportsnreports.com/ ) library of 200,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.